Beyond Cisplatin: Combination Therapy with Arsenic Trioxide

Area of Science:

• Inorganic Chemistry
• Medicinal Chemistry
• Cancer Pharmacology

Background:

• Platinum-based drugs (cisplatin, oxaliplatin, carboplatin) and arsenic trioxide are FDA-approved inorganic anticancer agents.
• These drugs possess distinct mechanisms of action, suggesting potential synergistic therapeutic benefits.
• Current research focuses on combining their anticancer activities for improved efficacy.

Purpose of the Study:

• To review preclinical studies on combining cisplatin and arsenic trioxide.
• To explore nanoformulation and co-encapsulation strategies for these drugs.
• To summarize the chemistry and cytotoxicity of novel arsenoplatin compounds.

Main Methods:

• Review of preclinical research on cisplatin and arsenic trioxide combinations.
• Analysis of studies involving co-encapsulation in nanoscale delivery systems.
• Examination of the development and characterization of small molecule agents with Pt-As bonds.

Main Results:

• Synergistic anticancer activity observed between cisplatin and arsenic trioxide.
• Development of novel nanoscale delivery systems for co-administration.
• Emergence of small molecule agents (arsenoplatin) with Pt-As bonds exhibiting broad anticancer activity.
• Arsenoplatins demonstrate robustness in physiological conditions and stable biopolymer complexation.

Conclusions:

• Combining cisplatin and arsenic trioxide offers a promising strategy for enhanced cancer therapy.
• Novel nanoformulations and arsenoplatin compounds represent significant advancements in inorganic anticancer drug development.
• Further preclinical investigation is warranted to translate these findings into clinical applications.